Last updated: 4 months ago
Tiziana Life Sciences LTD: 2025 Report on Nasal Anti-CD3 Antibody Findings
Tiziana Life Sciences LTD's 2025 foreign issuer report highlights findings on nasal anti-CD3 monoclonal antibody, addressing GLP-1 drug tolerability issues. Read more in Exhibit 99.1!